NEWS RELEASE

Teijin, J-TEC, Mitsui Fudosan and NCC to Establish
Regenerative Medicine Platform
Tokyo, Japan, September 27, 2022 --- Teijin Limited, Japan Tissue Engineering Co.,
Ltd. (J-TEC), Mitsui Fudosan Co., Ltd. and the National Cancer Center (NCC) jointly
announced today that they will establish a regenerative medicine platform in
Kashiwanoha Smart City, a life science business park in Kashiwa-shi, Chiba Prefecture,
Japan. The platform supports the development of innovative treatments for diseases withunmet needs such as cancer. It serves a one-stop system supporting research anddevelopment, business plan formulation, and commercial production of regenerativemedicine products. In particular, the four partners aim to accelerate thecommercialization of regenerative medicine and innovative treatments for cancer. As
part of the plan, the partners already have begun to support seed holders.
Looking at the four partners: NCC provides cutting-edge cancer treatments and produces
drug discovery seeds; J-TEC has extensive experience in product development,
manufacturing and marketing as a pioneer of regenerative medicines; Teijin boasts
expertise in drug research, development and marketing; and Mitsui Fudosan builds
spaces and communities for innovation in life sciences. Their envisioned platform, taking
advantage of the physical and functional proximity of the four parties, is expected toquickly and efficiently provide solutions for manufacturing and clinical development,
business planning and commercial production. The contract development andmanufacturing organization (CDMO) served by Teijin and J-TEC will be located in Mitsui
Link-Lab Kashiwanoha 1 operated by Mitsui Fudosan, and is adjacent to the NCC
Hospital East and NCC Exploratory Oncology Research & Clinical Trial Center.
The platform will also support projects of other organizations that have seeds. NCC will
provide professional consulting and collaboration with seeds holders and investigatorinitiated clinical trials. Teijin and J-TEC offer practical consulting and support forcontracted development and manufacturing. Mitsui Fudosan will be responsible forvenue operation and providing support for individual initiatives.
In preparation to start up the CDMO facility scheduled to open in January 2024, theplatform will promote the development of regenerative medicines among academic
institutions, start-up companies, pharmaceutical companies and others. It also will solicit
research and development and clinical collaborations with medical institutions as well as
key opinion leaders (KOL) and business enterprises in the fields of cancer andregenerative medicine.

With this agreement, the four parties will strive to stimulate demand and build up theirplatform, aiming eventually at establishing a structure capable of supporting about 10projects annually with the purpose of bringing regenerative medicines to market. Teijin,
in collaboration with J-TEC, will invest a substantial portion of its more than JPY 3 billion
CDMO-related investment budget into the project, mainly for facilities and humanresource training in Mitsui Link-Lab Kashiwanoha 1 over the next two to three years,
thereby helping to establish a CDMO facility mainly for supporting the development ofmanufacturing methods as well as actual manufacturing. Ultimately, the four parties
expect to contribute to global medical care by providing new options for patients waiting
for innovative treatments.
According to the NCC, some one million people are diagnosed with cancer each year inJapan. Development of innovative treatments using regenerative medicines, includinggenetically modified immune cell therapy, also known as chimeric antigen receptor(CAR-T) cell therapy, has been ongoing worldwide in recent years. In addition, researchand development of promising treatments and their seeds are under way. Meanwhile,
the practical application of regenerative medicine requires specialized knowledge andpractical experience regarding matters such as pharmaceutical approval and quality
control. A wide range of commercialization knowhow also is required. As a result, many
academic institutions and start-up companies are unable to commercialize their researchand development independently. Teijin, J-TEC, Mitsui Fudosan and NCC, based on theirclear understanding of such needs, have now agreed to establish a regenerative
medicine platform to provide academic institutions with professional expertise andcommercialization knowhow on a collaborative basis.
Kashiwa-no-ha Smart City, which is served by Kashiwa-no-ha Campus Station about
30 minutes by express train from central Tokyo, is an area with accumulation of Japan’sleading academic and medical institutions for someof Japan's leading academia and medical facilities.
In addition to Mitsui Garden Hotel Kashiwa-no-ha
Parkside, which supports cancer patients, the smart
city has become a lively community of offices andcommercial facilities. Mitsui Link Lab Kashiwanoha 1,located at 6-6-2 Kashiwanoha, Kashiwa-shi, Chiba
Prefecture, comprises about 11,000 m2 of total floor space and offers rental space of about
8,000 m2.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD
9.4 billion) in the fiscal year that ended on March 31, 2022.
Please visit www.teijin.com
About J-TEC
J-TEC (TSE: 7774) is a maker of regenerative medical products whose corporate vision
is “creating a future for regenerative medicine,” and has been a member of the TeijinGroup since March 2021. As Japan’s top runner in regenerative medicine, J-TEC
obtained marketing approval for autologous cultured epidermis “JACE”, Japan’s firstregenerative medical product, in October of 2007, and began marketing the product inJanuary of 2009. J-TEC then went on to obtain marketing approval for Autologous
Cultured Cartilage “JACC” in July of 2012, for Autologous Cultured Corneal Epithelium“Nepic” in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium “Ocural”
in June 2021. Of the 16 regenerative medical products that have been approved in Japan,
four are J-TEC products. By making the most of the experience and knowhow cultivatedthrough these achievements, J-TEC is engaging in contract development of regenerativemedical products, consulting, and contract manufacture of specific cell-processedproducts.
Please visit www.jpte.co.jp/en/
About Mitsui Fudosan Co., Ltd.
(Kashiwa-no-ha Smart City: https://www.kashiwanoha-smartcity.com/en/)
Mitsui Fudosan is a comprehensive developer that creates new value by striving toresolve social issues through urban development. At Kashiwa-no-ha Smart City, Mitsui
Fudosan aims to create a smart, compact city driven by data through the introduction ofnew technologies such as AI and IoT. It has been selected by the Ministry of Land,
Infrastructure, Transport and Tourism as an advanced model project for a smart city
towards realizing Society 5.0. Going forward, Mitsui Fudosan will work on developing
smart medical institution services for health and medicine. In addition, the Mitsui
Fudosan Group believes that it can contribute significantly to the realization of Society
5.0, which is advocated by the Japanese government, and to the achievement of theSDGs, by promoting ESG management, which means advancing businesses based on
an awareness of the Environment (E), Society (S), and Governance (G).
About National Cancer Center JapanThe National Cancer Center Japan, established in 1962, is a leading medical institution
in cancer treatment and research in Japan. It is actively involved in physician-led clinical
trials and clinical research, and has produced a wealth of research results that have led
to the development of new drugs.
Press Contact
Corporate Communications
Teijin Limited+81 (0)3 3506 4055
pr@teijin.co.jp
Corporate Communication Office
Japan Tissue Engineering Co., Ltd.
+81 (0) 533 66 2020
jtec-info@jpte.co.jp
Public Relations Department
Mitsui Fudosan Co., Ltd.
+81 (0)3 3246 3155
Office of Public Relations, Strategic Planning Bureau
National Cancer Center
ncc-admin@ncc.go.jp